Genetically Engineered Insulin
Overview
Insulin is a vital hormone for blood sugar regulation, particularly important for managing diabetes. Historically, insulin was extracted from the pancreas of animals, but this practice often led to allergic reactions and was not sustainable for large populations.
Production Using Recombinant DNA Technology
In 1983, Eli Lilly developed a breakthrough process utilizing recombinant DNA (rDNA) technology. By introducing DNA sequences corresponding to insulin's two chains (A and B) into plasmids within E. coli bacteria, researchers were able to produce these chains separately. The chains are then combined to form functional human insulin through the creation of disulfide bonds.
Significance
This revolutionary production method not only addressed the insufficiency of animal-derived insulin but also ensured that the insulin produced is structurally identical to human insulin, significantly reducing the likelihood of immune responses. The ability to produce large quantities of insulin safely had a profound impact on diabetes management, enabling better health outcomes for millions of people worldwide.